Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

1.
2.
3.

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.

Bavdekar A, Oswal J, Ramanan PV, Aundhkar C, Venugopal P, Kapse D, Miller T, McGray S, Zehrung D, Kulkarni PS; SII MMR author group.

Vaccine. 2018 Feb 21;36(9):1220-1226. doi: 10.1016/j.vaccine.2018.01.006. Epub 2018 Feb 1.

4.

Effectiveness of a smartphone app to increase parents' knowledge and empowerment in the MMR vaccination decision: A randomized controlled trial.

Fadda M, Galimberti E, Fiordelli M, Romanò L, Zanetti A, Schulz PJ.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2512-2521. doi: 10.1080/21645515.2017.1360456. Epub 2017 Nov 10.

5.

Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.

Berry AA, Abu-Elyazeed R, Diaz-Perez C, Mufson MA, Harrison CJ, Leonardi M, Twiggs JD, Peltier C, Grogg S, Carbayo A, Shapiro S, Povey M, Baccarini C, Innis BL, Henry O.

Hum Vaccin Immunother. 2017 Jul 3;13(7):1516-1522. doi: 10.1080/21645515.2017.1309486. Epub 2017 May 8.

6.

Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.

Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, Mahapatro S, Sanmukhani J, Gupta G, Mittal R, Glueck R.

Hum Vaccin Immunother. 2017 Jul 3;13(7):1523-1530. doi: 10.1080/21645515.2017.1302629. Epub 2017 Mar 31.

7.

The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.

Durando P, Esposito S, Bona G, Cuccia M, Desole MG, Ferrera G, Gabutti G, Pellegrino A, Salvini F, Henry O, Povey M, Marchetti F.

Vaccine. 2016 Aug 5;34(36):4278-84. doi: 10.1016/j.vaccine.2016.07.009. Epub 2016 Jul 14.

8.

Evaluation of Vaccines Injection Order on Pain Score of Intramuscular Injection of Diphtheria, Whole Cell Pertussis and Tetanus Vaccine.

Fallah R, Gholami H, Ferdosian F, Binesh F.

Indian J Pediatr. 2016 Nov;83(12-13):1405-1409. doi: 10.1007/s12098-016-2186-z. Epub 2016 Jul 2.

PMID:
27371264
9.

A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzuela R, Stek JE, Helmond FA.

Hum Vaccin Immunother. 2016 Aug 2;12(8):2188-2196. Epub 2016 May 5.

10.

Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.

Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, Povey M, Da Costa C, Nicholson O, Innis BL.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):339-48. doi: 10.1093/jpids/piu081. Epub 2014 Aug 7.

11.

Text message reminders for timely routine MMR vaccination: A randomized controlled trial.

Hofstetter AM, DuRivage N, Vargas CY, Camargo S, Vawdrey DK, Fisher A, Stockwell MS.

Vaccine. 2015 Oct 26;33(43):5741-5746. doi: 10.1016/j.vaccine.2015.09.042. Epub 2015 Sep 28.

12.

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.

Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O.

BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202.

13.

First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers.

Crevat D, Brion JD, Gailhardou S, Laot TM, Capeding MR.

Pediatr Infect Dis J. 2015 Aug;34(8):884-92. doi: 10.1097/INF.0000000000000752.

PMID:
25966916
14.

Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study.

Shaheen MA, Salem SA, Fouad DA, El-Fatah AA.

Dermatol Ther. 2015 Jul-Aug;28(4):194-200. doi: 10.1111/dth.12230. Epub 2015 Apr 6.

PMID:
25847793
15.

Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.

Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M.

Vaccine. 2015 May 11;33(20):2379-86. doi: 10.1016/j.vaccine.2015.02.070. Epub 2015 Mar 9.

PMID:
25765966
16.

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.

de Menezes Martins R, Curran B, Maia Mde L, Ribeiro Md, Camacho LA, da Silva Freire M, Yamamura AM, Siqueira MM, Lemos MC, de Albuquerque EM, von Doellinger Vdos R, Homma A, Saganic L, Jarrahian C, Royals M, Zehrung D.

Contemp Clin Trials. 2015 Mar;41:1-8. doi: 10.1016/j.cct.2014.11.014. Epub 2014 Dec 1.

17.

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).

Klopfer SO, Stek JE, Petrecz M, Reisinger KS, Black SB, Goveia MG, Nicholson O, Gardner JL, Grosso AD, Brown ML, Kuter BJ, Schödel FP.

Vaccine. 2014 Dec 12;32(52):7154-60. doi: 10.1016/j.vaccine.2014.08.067. Epub 2014 Sep 16.

PMID:
25219563
18.

Vaccine message framing and parents' intent to immunize their infants for MMR.

Hendrix KS, Finnell SM, Zimet GD, Sturm LA, Lane KA, Downs SM.

Pediatrics. 2014 Sep;134(3):e675-83. doi: 10.1542/peds.2013-4077. Epub 2014 Aug 18.

19.

Cost effectiveness of a web-based decision aid for parents deciding about MMR vaccination: a three-arm cluster randomised controlled trial in primary care.

Tubeuf S, Edlin R, Shourie S, Cheater FM, Bekker H, Jackson C.

Br J Gen Pract. 2014 Aug;64(625):e493-9. doi: 10.3399/bjgp14X680977.

20.

Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach.

Nofal A, Nofal E, Yosef A, Nofal H.

Int J Dermatol. 2015 Jun;54(6):667-71. doi: 10.1111/ijd.12480. Epub 2014 Jul 29.

PMID:
25070525

Supplemental Content

Loading ...
Support Center